---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-297992"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2026-07-08T11:17:42+00:00"
generated_at: "2026-07-08T11:20:06.233876+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences appoints Jeremy Bender to Board of Directors; updates director compensation policy

## Summary
- Jeremy Bender, Ph.D., M.B.A., appointed as Class II director effective July 7, 2026; term expires at 2029 annual meeting.
- Bender appointed to Compensation Committee and Nominating and Corporate Governance Committee.
- Received initial option award for 60,000 shares and RSU award for 30,000 shares, vesting over three years.
- Board amended Non-Employee Director Compensation Policy on June 11, 2026, increasing initial option award from 34,000 to 60,000 shares and annual option award from 17,000 to 30,000 shares.
- Bender previously CEO of Day One Biopharmaceuticals, led acquisition by Servier for ~$2.5B in 2026.

## SEC filing metadata
- accession: 0001193125-26-297992
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2026-07-08T11:17:42+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312526297992/0001193125-26-297992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312526297992/aura-20260703.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-297992
- JSON: https://secwatch.observer/filing/0001193125-26-297992.json
- Plain text: https://secwatch.observer/filing/0001193125-26-297992.txt

## Key facts
- Executive change
  Jeremy Bender was appointed as Class II Director at Aura Biosciences, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On July 3, 2026, the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) increased the size of the Board from six to seven directors and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II director, effective July 7, 2026 (the “Effective Date”), to fill the newly created vacancy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000119312526297992/0001193125-26-297992-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.